Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

Open access

Abstract

Background: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy (ACT) decisions is non-inferior to standard of care (SOC) chemotherapy, as measured by 3-year disease free survival (DFS) in patients with resected CRC with no evidence of MRD (ctDNA negative post-operatively). In doing so we may be able to spare patients unnecessary chemotherapy and associated toxicity and achieve significant cost savings for the National Health Service (NHS). Methods: We are recruiting patients with fully resected high risk stage II and stage III CRC who are being considered for ACT into the study which uses results from a plasma-only ctDNA assay to guide treatment decisions. Eligible patients are randomised 1:1 to receive ctDNA-guided chemotherapy versus SOC chemotherapy. The primary endpoint is the difference in DFS at 3 years between the trial arms. Secondary endpoints include the proportion of patients in the ctDNA-guided arm who are ctDNA negative post-operatively and receive de-escalated ACT compared to the standard arm, the difference in overall survival (OS), neurotoxicity and quality of life between the arms, and the cost-effectiveness of ctDNA-guided therapy compared to SOC treatment. We hypothesise that using a ctDNA-guided approach to ACT decisions is non-inferior to SOC. Target accrual is 1621 patients over 4 years, which will provide a power of 80% with an alpha of 0.1 to demonstrate non-inferiority with a margin of 1.25 in survival of the ctDNA-guided approach compared to SOC. We anticipate approximately 50 UK centres will participate. The study opened with the Guardant Reveal plasma-only ctDNA assay in August 2022. Discussion: The trial will determine whether ctDNA guided ACT is non-inferior to SOC ACT in patients with fully resected high risk stage II and stage III resected CRC, with the potential to significantly reduce unnecessary ACT and the toxicity associated with it. Trial registration: NCT04050345.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-023-10699-4

Cites

Statistics

Figures

Fig. 1 Study schema for TRACC Part C
Fig. 1 Study schema for TRACC Part CCC BY · PubMed Central
Fig. 2 De-escalation/escalation strategy in ctDNA negative group in the ctDNA-guided arm
Fig. 2 De-escalation/escalation strategy in ctDNA negative group in the ctDNA-guided armCC BY · PubMed Central
Fig. 3 Follow up schedule for blood sample collection and CT imaging
Fig. 3 Follow up schedule for blood sample collection and CT imagingCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 19 · Cited by 37

Metadata

Authors
Slater, S., Bryant, A., Chen, H.-C., Begum, R., Rana, I., Aresu, M., Peckitt, C., Zhitkov, O., Lazaro-Alcausi, R., Borja, V., Powell, R., Lowery, D., Hubank, M., Rich, T., Anandappa, G., Chau, I., Starling, N., & Cunningham, D.
Affiliations
  • Royal Marsden NHS Foundation Trust (GB)
  • Institute of Cancer Research (GB)
  • Guardant (United States) (US)
Corresponding author
Cunningham, David
Venue
BMC Cancer
Published
2023-03-20
Volume
23
Issue
1
Pages
257-257
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4327972762
Cited by
37
References
19
Citations by year
2026: 12 · 2025: 9 · 2024: 14 · 2023: 2
FWCI
4.51
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute for Health and Care Research (NIHR-INF-2174, NIHR128529)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
circulating tumor DNA, minimal residual disease, adjuvant chemotherapy, de-escalation, colorectal cancer, disease-free survival, non-inferiority, cost-effectiveness, neurotoxicity, quality of life, resected colorectal cancer, TRACC
MeSH terms
Humans, Prospective Studies, Quality of Life, State Medicine, Colorectal Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). https://app.cochat.ai/papers/10.1186/s12885-023-10699-4
The paper
Slater, S., Bryant, A., Chen, H.-C., Begum, R., Rana, I., Aresu, M., Peckitt, C., Zhitkov, O., Lazaro-Alcausi, R., Borja, V., Powell, R., Lowery, D., Hubank, M., Rich, T., Anandappa, G., Chau, I., Starling, N., & Cunningham, D. (2023). ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). BMC Cancer. https://doi.org/10.1186/s12885-023-10699-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.